When we counted the total number of CD83+CCR7+ cells in each of the four groups (pre- or posttreatment melanoma samples from responders or non-responders to ICI), the proportion of CD83+CCR7+ cells within the CD8+ T cell population was higher in the responder group (43 of 1005 cells, 4.3%) than in the non-responder group (26 of 1587 cells, 1.6%) at baseline, which significantly decreased after ICI treatment (25 of 1082 cells, 2.3%) (Fig. 7d). This evidence concerns the gene CD8A and melanoma.